PCM
AMRI

Prelude Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Prelude Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-368,504
Closed -$8M – 2095
2017
Q2 		$8M Buy
+368,504
New +$6.69M 0.76% 30
2016
Q4 		– Sell
-8,296
Closed -$137K – 1954
2016
Q3 		$137K Buy
+8,296
New +$123K 0.01% 710
2015
Q4 		– Sell
-19,000
Closed -$331K – 1850
2015
Q3 		$331K Buy
19,000
+300
+2% +$6.11K 0.05% 395
2015
Q2 		$378K Sell
18,700
-3,300
-15% -$63.7K 0.05% 380
2015
Q1 		$387K Buy
22,000
+7,000
+47% +$119K 0.05% 419
2014
Q4 		$244K Sell
15,000
-15,000
-50% -$275K 0.04% 571
2014
Q3 		$662K Sell
30,000
-200
-0.7% -$4.09K 0.09% 267
2014
Q2 		$608K Buy
30,200
+200
+0.7% +$3.39K 0.08% 315
2014
Q1 		$558K Hold
30,000
– – 0.07% 354
2013
Q4 		$302K Hold
30,000
– – 0.05% 497
2013
Q3 		$387K Hold
30,000
– – 0.06% 360
2013
Q2 		$356K Buy
+30,000
New +$325K 0.08% 322

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Prelude Capital Management's AMRI Position: Q3 2017 in Review

Prelude Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 368,504 shares — an estimated $8M sold.

Prelude Capital Management first reported a position in AMRI in Q2 2013 and held it in 12 quarters. The position peaked at $8M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Prelude Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 368,504 Albany Molecular Research Inc shares in Q3 2017, an estimated $8M.
  • Prelude Capital Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 12 quarters.
  • Prelude Capital Management's Albany Molecular Research Inc position peaked at $8M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.